ATE479101T1 - Verfahren zur quantifizierung von denaturiertem lipoprotein - Google Patents

Verfahren zur quantifizierung von denaturiertem lipoprotein

Info

Publication number
ATE479101T1
ATE479101T1 AT02746016T AT02746016T ATE479101T1 AT E479101 T1 ATE479101 T1 AT E479101T1 AT 02746016 T AT02746016 T AT 02746016T AT 02746016 T AT02746016 T AT 02746016T AT E479101 T1 ATE479101 T1 AT E479101T1
Authority
AT
Austria
Prior art keywords
lipoprotein
antibody against
denaturated
quantifying
determining
Prior art date
Application number
AT02746016T
Other languages
English (en)
Inventor
Hiroaki Kohno
T Yanagisawa
T Masunari
Original Assignee
Kyowa Medex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Medex Co Ltd filed Critical Kyowa Medex Co Ltd
Application granted granted Critical
Publication of ATE479101T1 publication Critical patent/ATE479101T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
AT02746016T 2001-07-12 2002-07-12 Verfahren zur quantifizierung von denaturiertem lipoprotein ATE479101T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001212522 2001-07-12
PCT/JP2002/007116 WO2003006989A1 (fr) 2001-07-12 2002-07-12 Procede de quantification de lipoproteines denaturees, reactifs pour la quantification de lipoproteines denaturees, procede de detection de maladies du systeme circulatoire et reactifs pour la detection de maladies du systeme circulatoire

Publications (1)

Publication Number Publication Date
ATE479101T1 true ATE479101T1 (de) 2010-09-15

Family

ID=19047672

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02746016T ATE479101T1 (de) 2001-07-12 2002-07-12 Verfahren zur quantifizierung von denaturiertem lipoprotein

Country Status (9)

Country Link
US (1) US20040241744A1 (de)
EP (1) EP1418429B1 (de)
JP (2) JP4179988B2 (de)
KR (1) KR20040025931A (de)
CN (1) CN100516878C (de)
AT (1) ATE479101T1 (de)
CA (1) CA2453538A1 (de)
DE (1) DE60237455D1 (de)
WO (1) WO2003006989A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE546734T1 (de) * 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US7807378B2 (en) * 2005-12-29 2010-10-05 Industrial Technology Research Institute (Itri) Method of diagnosing myasthenia gravis and kits therefor
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CN101772701B (zh) * 2007-06-08 2014-10-15 奎斯特诊断投资公司 通过差分带电荷微粒迁移率进行脂蛋白分析
US20110104823A1 (en) * 2008-07-11 2011-05-05 Owen Whyte G Measuring lipoprotein containing particles
EP2324354B1 (de) * 2008-08-29 2014-07-16 Astute Medical, Inc. Verfahren zur prognose von akuter niereninsuffizienz
CN104399089B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2010101206A1 (ja) * 2009-03-05 2010-09-10 株式会社ビー・エム・エル 管理試料の安定化剤、当該安定化剤を含有する管理試料、及び、当該管理試料を含む測定用キット
US20120149131A1 (en) * 2009-08-28 2012-06-14 B.R.A.H.M.S Gmbh Procalcitonin for the prognosis of adverse events
US20130045494A1 (en) * 2009-09-18 2013-02-21 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP6231307B2 (ja) * 2013-06-27 2017-11-15 中野 恵正 機能不全ｈｄｌの測定方法、機能不全ｈｄｌ測定用キット、並びに、生活習慣病マーカーの測定方法
KR20160091276A (ko) 2015-01-23 2016-08-02 바디텍메드(주) Cdc 단백질 및 콜레스테롤 항체를 이용한 콜레스테롤 측정 방법
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP6859215B2 (ja) * 2017-04-17 2021-04-14 日本光電工業株式会社 脂質二重膜粒子またはその断片の検出方法
CN107271674B (zh) * 2017-06-13 2019-05-07 首都医科大学附属北京地坛医院 一种用于脂肪性肝炎检测的靶标志物gp73及检测应用方法
CN107807245A (zh) * 2017-10-25 2018-03-16 阮雄中 一种细胞内胆固醇敏感度和定位的测量方法及其诊断试剂
US20230288437A1 (en) * 2020-03-30 2023-09-14 Shinshu University Quantification method for modified hdl, and analysis reagent for use in same method
CN117716234A (zh) * 2022-01-03 2024-03-15 科尔仕公司 用于从样本中分离阴电性低密度脂蛋白的生物试剂套组、试剂溶液以及从样本中分离阴电性低密度脂蛋白的方法
WO2023167232A1 (ja) * 2022-03-01 2023-09-07 旭化成ファーマ株式会社 オートタキシン測定試薬のキャリブレーター、オートタキシン測定試薬のキャリブレーション方法、オートタキシン測定キット、オートタキシンの測定方法、診断補助キット、及び診断補助方法
CN117192134A (zh) * 2023-09-14 2023-12-08 宁波美康盛德生物科技有限公司 一种氧化型低密度脂蛋白的检测试剂盒、检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
ES2070820T3 (es) * 1986-08-06 1995-06-16 Scripps Clinic Res Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
US4828986A (en) * 1986-09-29 1989-05-09 Scripps Clinic And Research Foundation Assay method and diagnostic system for determining the ratio of APO B-100 to APO A-I in a blood sample
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
JPH07104351B2 (ja) * 1988-09-29 1995-11-13 株式会社日本抗体研究所 脂質代謝異常検出用キット
JP3356556B2 (ja) * 1993-10-22 2002-12-16 第一化学薬品株式会社 変性リポプロテイン類の測定法
JPH08228774A (ja) * 1995-02-27 1996-09-10 Toagosei Co Ltd ペルオキシダーゼまたはペルオキシダーゼ標識抗体の安定化方法
US5689961A (en) * 1996-01-30 1997-11-25 Organogenesis Inc. Ice seeding apparatus for cryopreservation systems
JP3872880B2 (ja) * 1997-10-21 2007-01-24 アルフレッサファーマ株式会社 感作金属コロイド含有安定化凍結乾燥物及びその製造方法
ATE250228T1 (de) * 1998-07-03 2003-10-15 Athera Biotechnologies Ab Verfahren zur diagnose von gefässerkrankungen und früher atheriosklerose
CA2375868C (en) * 1999-06-02 2012-10-30 Vessel Research Laboratory Co., Ltd. Stabilized denatured lipoprotein and method for producing thereof
JP3491743B2 (ja) * 1999-08-31 2004-01-26 株式会社いかがく 血液中の変性リポ蛋白の検出方法

Also Published As

Publication number Publication date
WO2003006989A1 (fr) 2003-01-23
CN100516878C (zh) 2009-07-22
EP1418429A1 (de) 2004-05-12
EP1418429B1 (de) 2010-08-25
CN1554024A (zh) 2004-12-08
JP4179988B2 (ja) 2008-11-12
KR20040025931A (ko) 2004-03-26
US20040241744A1 (en) 2004-12-02
JP4904308B2 (ja) 2012-03-28
EP1418429A4 (de) 2008-04-02
JPWO2003006989A1 (ja) 2004-11-04
CA2453538A1 (en) 2003-01-23
JP2008203269A (ja) 2008-09-04
DE60237455D1 (de) 2010-10-07

Similar Documents

Publication Publication Date Title
ATE479101T1 (de) Verfahren zur quantifizierung von denaturiertem lipoprotein
ATE405832T1 (de) Verfahren zur erhöhung des dynamischen messbereichs von auf spezifischen bindereaktionen basierenden, insbesondere immunologischen testelementen
ATE516492T1 (de) Vorrichtung und verfahren zur multianalytbestimmung
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
DE69839149D1 (de) Methode und vorrichtung zum nachweis oder zur quantifizierung von kohlenhydrate enthaltenden verbindungen
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
DE602005013225D1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
DE69920937D1 (de) Verfahren zur quantifizierung von cholesterol in lipoproteinen und quantifizierungsreagenzien
DE502004008216D1 (de) Vorrichtung und verfahren zur simultanen durchführung von blutgruppenbestimmung, serumgegenprobe und antikörpersuch-test
WO2006047591A3 (en) Rapid microfluidic assay for analyte interactions
DE60144551D1 (de) Immunologisch-analytisches Verfahren zur Bestimmung von glykosylierten Proteinen (AGEs)
ATE545460T1 (de) Proteomanalyseverfahren für phosphoryliertes protein
DE60021369D1 (de) Verfahren zur abschätzung eines magengeschwür-risikos
CY1114429T1 (el) Μεθοδος και διαταξη για την αναλυση αρκετων αναλυτων ταυτοχρονα με εναν εσωτερικο ελεγχο
GB2437545B (en) Dextrin-containing reagents for detecting and quantifying proteins
ATE333091T1 (de) Verfahren zur messung von blutersatzstoffen
ATE462975T1 (de) Verfahren zum immunochemischen testen des anti- hm1.24-antikörpers
ATE368855T1 (de) Immunnephelometrie von lipoprotein (a) und reagens dafür
WO2003029813A3 (de) Teststreifen für den nachweis von prionproteinen
ATE421093T1 (de) Schnelle bestimmung verschiedener formen von hgf (heptocyte growth factor) in den körperflüssigkeiten
DE60121547D1 (de) Electrochemisches verfahren zum nachweis von nukleinsäuren
ATE278965T1 (de) Knorpelresorptionsassays
ATE520985T1 (de) Verfahren zur bestimmung von antigen und antikörper gegen das antigen
DE60216482D1 (de) Zusammensetzungen und verfahren zum bestimmen von aa4rp
RU2001132334A (ru) Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties